Events

AI Drug Discovery Summit w/ Dane Corneil

Join Dane Corneil, Lead AI Scientist for Target Identification, for a talk on “Large Language Models for Target Identification” at the AI Driven Drug Discovery Summit

Dane will discuss recent advances in large language modeling to predict drug targets from vast literature corpuses, how to evaluate language models for production readiness and how to combine language models with knowledge graphs to leverage multimodal data sources.

Event website  — >


Dane Corneil

AI Lead Scientist

Dane is the Target ID AI Team Lead at BenevolentAI, where his work focuses on building models to flexibly identify novel therapeutic targets in an interpretable way. He holds PhD and Masters degrees in computational neuroscience, with a particular focus on model-based reinforcement learning.

More Posts

You Might Also Like

Blog
Fueling continuous innovation at BenevolentAI
BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.
Jul 22, 2022
News
BenevolentAI appoints GSK drug discovery veteran Dr Nicola Richmond as Vice President of AI
As VP of AI, Dr Nicola Richmond will be responsible for spearheading BenevolentAI’s AI strategy and working to ensure the Company maintains its leading position in AI-enabled drug discovery.
Jul 6, 2022
News
BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022